DZD8586 demonstrated encouraging anti-tumor activity with manageable safety and favorable pharmacokinetic (PK) characteristics in patients with B-NHL

SHANGHAI,Dec. 9,2024 -- Dizal (SSE:688192),a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases,announced the latest data from a pooled safety and efficacy analysis of DZD8586,a non-covalent blood-brain barrier (BBB)penetrantLYN/BTK dual inhibitor,in B-cell non-Hodgkin lymphoma (B-NHL). The data were presented at the 66th American Society of Hematology (ASH) Annual Meeting.

The analysis pooled data from ongoing phase 1/2 clinical studies evaluating DZD8586 in patients with B-NHL who had progressed following,or were intolerant to,prior systemic therapies. As of October 20,2024,61 patients were included in the efficacy analysis and 84 patients were included in the safety set.

Anti-tumor efficacy:

In chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL),the overall response rate (ORR) was 57.9% (≥ 50 mg) by data cutoff. Tumor response was observed in patients with prior treatment of covalent and non-covalent BTKi,and Bcl-2i. Tumor responses were observed in patients with classic BTK resistance mutations (C481X) as well as BTK "dead" mutations. Preliminary anti-tumor activity was observed in patients pre-treated by pirtobrutinib,with T474I mutation as well.

Significant tumor response was also observed in other B-NHL,including diffuse large B-cell lymphoma (DLBCL),follicular lymphoma (FL),mantle cell lymphoma (MCL),marginal zone B-cell lymphoma (MZL),and central nervous system lymphoma (CNSL).

Safety:

Dose-dependent thrombocytopenia and neutropenia were the most common ≥grade 3 TEAEs,which could be well managed in the clinic.

PK and pharmacodynamic biomarker

Dose-proportional PK profile and dose-dependent modulation of pharmacodynamic biomarkers were observed.

In patients with CNSL,the Kpuu,CSF at steady state were 1.21 and 0.98,suggesting high CNS penetration of DZD8586 in human.

"A significant proportion of B-NHL patients treated with BTK inhibitors will eventually relapse and develop drug-resistant mutations. Two primary types of clinical resistance mutations have been identified: C481X mutation and BTK loss-of-activity mutations,"said Xiaolin Zhang,PhD,CEO of Dizal. "DZD8586,as a non-covalent dual inhibitor targeting both BTK-dependent and -independent pathways,has demonstrated promising antitumor activity and safety profile in patients who did not respond to or develop resistance to both covalent and non-covalent BTK inhibitors,including those with CLL/SLL and other B-NHL. With multiple clinical development programs ongoing or under planning,DZD8586 is expected to bring significant clinical benefit to patients with relapsed or refractory B-NHL."

Bruton's Tyrosine Kinase (BTK) inhibitors have revolutionized the treatment of B-cell lymphomas. However,resistance can arise through multiple mechanisms,compromising the treatment outcome and posing an urgent clinical challenge. The C481X mutation disrupts covalent BTK inhibitors binding to BTK enzyme and leads to treatment failure. Additionally,BTK-independent resistance mechanism due to loss of or much diminished BTK enzyme activity was also identified in the clinic. Currently,there is no targeted therapy available to address both resistance mechanisms.

DZD8586 was designed as a LYN/BTK dual inhibitor with high selectivity against other TEC family kinases (TEC,ITK,TXK and BMX),as well as full BBB penetration. By targeting BTK and LYN,it blocks both BTK-dependent and -independent BCR-signaling pathways,which may potentially overcome resistance to approved covalent and non-covalent BTK inhibitors.

References：

[1] Constantine Tam,Philip A. Thompson,BTK inhibitors in CLL: second-generation drugs and beyond,Blood Advances,Volume 8,Issue 9,Pages 2300-2309.

[2] Jennifer A. Woyach,et al. Blood 2024; 144 (10): 1061–1068.

[3] Manli Jiang,Nabila Bennani-Baiti & Andrew L. Feldman (2017): Lymphoma classification update: B-cell non-Hodgkin lymphomas,Expert Review of Hematology,2017.1318053.

[4] Solimando AG,Ribatti D,Vacca A,Einsele H. Targeting B-cell non-Hodgkin lymphoma: New and old tricks. Leuk Res. 2016 Mar; 42:93-104.

About DZD8586

DZD8586 is an oral,highly selective,non-covalent LYN/BTK dual inhibitor to target both BTK-dependent and BTK-independent B-cell receptor (BCR) signaling pathways,with full blood-brain barrier penetration. Pre-clinical research revealed that DZD8586 demonstrated good safety profile and could effectively inhibit the growth of B-NHL cells. A healthy volunteer study of DZD8586 has been completed to investigate the clinical safety and PK/PD correlation. Global phase I/II studies are ongoing to evaluate the safety,tolerability,pharmacokinetics,and anti-tumor efficacy of DZD8586 in patients with r/r B-NHL. Preliminary results from the clinical trials suggest that DZD8586 exhibits favorable PK properties,good safety profile,and preliminary anti-tumor efficacy in patients with B-NHL.

About Dizal

Dizal is a biopharmaceutical company,dedicated to the discovery,development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines,and further address unmet medical needs worldwide. Deep-rooted in translational science and molecular design,it has established an internationally competitive portfolio with two leading assets in global pivotal studies,both of which have already been launched in China.

To learn more about Dizal,please visitwww.dizalpharma.com,or follow us onLinkedinorTwitter.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are,by their nature,subject to significant risks and uncertainties. The words "anticipate","believe","estimate","expect",and "intend" and similar expressions,as they relate to Dizal,are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs,assumptions,expectations,estimates,projections,and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks,uncertainties,and other factors,some of which are beyond Dizal's control and are difficult to predict. Consequently,actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business,Dizal's competitive environment,and political,economic,legal,and social conditions.

Dizal,the Directors,and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.

Contacts

Investor Relations: ir@dizalpharma.com

Business Development: bd@dizalpharma.com

Media Contact: pr@dizalpharma.com